logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Patient Registry Software Market, By Type (Diabetes, Drugs, Asthma, Cancer, Orthopaedic), By Software (Standalone, integrated) By delivery methods (Cloud based, On-Premise) opportunities and forecast 2020-2027

  • DLR2202
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Patient registry software deals with organized system, that uses observational methods to collect the uniform data (clinical and various other) for evaluation of definite outcomes for population, defined by specific condition, disease, or exposure, and which additionally serves one or more of the predetermined clinical, scientific, or policy purposes.

Number of factors including government initiatives to build the patient registries, increasing pressure to increase the quality of care and reduce the healthcare costs, along with rising adoption of Electronic Health Records (EHRs), and growing use of the patient registry data for various post-marketing surveillance are propelling the growth of the market. However, data security and privacy related concerns coupled with lack of skilled and trained resources are some of the major factors restraining the growth of this market.

Segment Overview

On the basis of type of registry, the patient registry software market is segmented as drug, diabetes, cancer, and asthma and orthopaedic. The diabetes registries segment is projected to account for largest share of the of the patient registry software market in 2019. This is predominantly attributed to the growing prevalence of various chronic diseases, rising awareness about importance of the patient registries, growing government initiatives to construct disease registries, and the increasing adoption of the EHRs across the globe.

Similarly, based on type of the software, the market has been segmented as two segments, namely, integrated and standalone software. The standalone software segment is projected to dominate the market during the forecast period owing to the rising need and focus on safeguarding an integrated healthcare system.

Regional Overview

North America commanded the major market share of patient registry software market in 2019. The high market share is largely attributed to the digital infrastructure development for the healthcare and the electronic health record implementation in the U.S..

The market in Asia Pacific is expected to register highest growth during the forecast period OF 2020 TO 2026. The growth is primarily driven by the huge population base, increasing prevalence of chronic diseases, developments in healthcare systems, and due to increasing government initiatives for modernization of the healthcare infrastructures. Additionally, continuing research activities in the region generate demand for the registry databases and, consequently, patient registry software in region.

Competitor overview

Owing to the better outcomes and increased quality of care in 21st century, the market players around the world are considering for cost-effective and innovative ways to deliver the technology-enabled, patient-centred healthcare solutions, both outside and inside the hospital walls. Furthermore, due to widespread applications, including non-clinical and clinical, electronic health records have attracted the attention from various government sources. Various federal policies, programs and actions are being introduced by the governments of various developed and developing countries around the world, in order to achieve progress in the healthcare services.

Key Players
  1. Dacima Software Inc.,
  2. FIGmd, Inc.,
  3. Global Vision Technologies, Inc.,
  4. Image Trend, Inc.,
  5. IQVIA,
  6. Liasion Technologies,
  7. McKensson Corporation,
  8. Syneos Health, and
  9. Velos Inc.,


Market Segmentation

By Type
  • Diabetes
  • Drugs
  • Asthma
  • Cancer
  • Orthopedic
By Software
  • Standalone
  • Integrated
By Delivery Methods
  • Cloud Based
  • On-Premise
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 EXECUTIVE SUMMARY 16

  • 1.1 OVERVIEW 16
    • 1.1.1 MARKET SYPNOSIS 16

2 MARKET INTRODUCTION 17

  • 2.1 SCOPE OF THE STUDY 17
  • 2.2 RESEARCH OBJECTIVE 17
  • 2.3 LIST OF ASSUMPTIONS 17

3 RESEARCH METHODOLOGY 19

  • 3.1 OVERVIEW 19
  • 3.2 DATA MINING 19
  • 3.3 SECONDARY RESEARCH 20
  • 3.4 PRIMARY RESEARCH 21
    • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21
    • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 22
  • 3.5 FORECASTING TECHNIQUES 22
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 23
    • 3.6.1 BOTTOM-UP APPROACH 24
    • 3.6.2 TOP-DOWN APPROACH 25
  • 3.7 DATA TRIANGULATION 26
  • 3.8 VALIDATION 26

4 MARKET DYNAMICS 27

  • 4.1 OVERVIEW 27
  • 4.2 DRIVERS 28
    • 4.2.1 HIGH ADOPTION RATE OF ELECTRONIC HEALTH RECORDS (EHRS) 28
    • 4.2.2 INCREASED GOVERNMENT INITIATIVES FOR THE IMPLEMENTATION OF PATIENT REGISTRIES 28
    • 4.2.3 GROWING USE OF PATIENT REGISTRY DATA FOR POST-MARKETING SURVEILLANCE 29
    • 4.2.4 RISING PRESSURE TO IMPROVE THE QUALITY OF CARE AND REDUCE HEALTHCARE COSTS 29
  • 4.3 RESTRAINTS 31
    • 4.3.1 PRIVACY- AND DATA SECURITY-RELATED CONCERNS 31
    • 4.3.2 LACK OF TRAINED AND SKILLED RESOURCES 31
  • 4.4 OPPORTUNITIES 32
    • 4.4.1 INCREASING NUMBER OF ACCOUNTABLE CARE ORGANIZATIONS 32
    • 4.4.2 SHIFTING FOCUS TOWARD PATIENT-POWERED RESEARCH NETWORKS (PPRNS) 33

5 MARKET FACTOR ANALYSIS 34

  • 5.1 PORTER’S FIVE FORCES MODEL 34
    • 5.1.1 BARGAINING POWER OF SUPPLIERS 34
    • 5.1.2 BARGAINING POWER OF BUYERS 35
    • 5.1.3 THREAT OF NEW ENTRANTS 35
    • 5.1.4 THREAT OF SUBSTITUTES 35
    • 5.1.5 INTENSITY OF RIVALRY 35
  • 5.2 VALUE CHAIN ANALYSIS 36
    • 5.2.1 INPUTS 37
    • 5.2.2 SOFTWARE DEVELOPMENT PROCESS 37
    • 5.2.3 OUTPUT 37
    • 5.2.4 MARKETING AND DISTRIBUTION 37
    • 5.2.5 POST-SELLING SERVICES 37

6 GLOBAL PATIENT REGISTRY SOFTWARE MARKET, BY TYPE OF REGISTRY 38

  • 6.1 OVERVIEW 38
  • 6.2 DISEASE REGISTRIES 40
  • 6.3 HEALTH SERVICE REGISTRIES 40
  • 6.4 PRODUCT REGISTRIES 41
  • 6.5 OTHERS 42

7 GLOBAL PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY 43

  • 7.1 OVERVIEW 43
  • 7.2 POPULATION HEALTH MANAGEMENT (PHM) 44
  • 7.3 PATIENT CARE MANAGEMENT 45
  • 7.4 HEALTH INFORMATION EXCHANGE (HIE) 46
  • 7.5 OTHERS 46

8 GLOBAL PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL 47

  • 8.1 OVERVIEW 47
  • 8.2 ON-PREMISE 48
  • 8.3 CLOUD 49

9 GLOBAL PATIENT REGISTRY SOFTWARE MARKET, BY END USER 50

  • 9.1 OVERVIEW 50
  • 9.2 HOSPITALS & CLINICS 51
  • 9.3 GOVERNMENT ORGANIZATIONS & RESEARCH CENTERS 52
  • 9.4 OTHERS 52

10 GLOBAL PATIENT REGISTRY SOFTWARE MARKET, BY REGION 53

  • 10.1 OVERVIEW 53
  • 10.2 AMERICAS 55
    • 10.2.1 NORTH AMERICA 58
      • 10.2.1.1 US 60
      • 10.2.1.2 CANADA 62
    • 10.2.2 LATIN AMERICA 63
  • 10.3 EUROPE 66
    • 10.3.1 WESTERN EUROPE 68
      • 10.3.1.1 GERMANY 71
      • 10.3.1.2 UK 72
      • 10.3.1.3 FRANCE 74
      • 10.3.1.4 ITALY 76
      • 10.3.1.5 SPAIN 77
      • 10.3.1.6 REST OF WESTERN EUROPE 79
    • 10.3.2 EASTERN EUROPE 81
  • 10.4 ASIA-PACIFIC 83
    • 10.4.1 CHINA 86
    • 10.4.2 JAPAN 87
    • 10.4.3 INDIA 89
    • 10.4.4 SOUTH KOREA 91
    • 10.4.5 AUSTRALIA 92
    • 10.4.6 REST OF ASIA-PACIFIC 94
  • 10.5 MIDDLE EAST & AFRICA 96
    • 10.5.1 MIDDLE EAST 98
    • 10.5.2 AFRICA 100

11 COMPETITIVE LANDSCAPE 102

  • 11.1 OVERVIEW 102
  • 11.2 COMPANY RANKING ANALYSIS 102
  • 11.3 COMPETITIVE BENCHMARKING 103
  • 11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 104
  • 11.5 KEY DEVELOPMENT ANALYSIS 104
    • 11.5.1 ACQUISITION 105
    • 11.5.2 EXPANSION 106
    • 11.5.3 PARTNERSHIP/MERGER 106
    • 11.5.4 PRODUCT/SERVICE LAUNCH 107

12 COMPANY PROFILE 108

  • 12.1 ARBORMETRIX 108
    • 12.1.1 COMPANY OVERVIEW 108
    • 12.1.2 FINANCIAL OVERVIEW 109
    • 12.1.3 PRODUCTS/SERVICES OFFERED 109
    • 12.1.4 KEY DEVELOPMENTS 110
    • 12.1.5 SWOT ANALYSIS 111
    • 12.1.6 KEY STRATEGIES 111
  • 12.2 DACIMA SOFTWARE INC. 112
    • 12.2.1 COMPANY OVERVIEW 112
    • 12.2.2 FINANCIAL OVERVIEW 112
    • 12.2.3 PRODUCTS/SERVICES OFFERED 113
    • 12.2.4 KEY DEVELOPMENTS 113
    • 12.2.5 SWOT ANALYSIS 114
    • 12.2.6 KEY STRATEGIES 114
  • 12.3 EVADO PTY. LTD 115
    • 12.3.1 COMPANY OVERVIEW 115
    • 12.3.2 FINANCIAL OVERVIEW 115
    • 12.3.3 PRODUCTS/SERVICES OFFERED 116
    • 12.3.4 KEY DEVELOPMENTS 116
    • 12.3.5 SWOT ANALYSIS 117
    • 12.3.6 KEY STRATEGIES 117
  • 12.4 IFA SYSTEMS 118
    • 12.4.1 COMPANY OVERVIEW 118
    • 12.4.2 FINANCIAL OVERVIEW 119
    • 12.4.3 PRODUCTS/SERVICES OFFERED 119
    • 12.4.4 KEY DEVELOPMENTS 119
    • 12.4.5 SWOT ANALYSIS 120
    • 12.4.6 KEY STRATEGIES 120
  • 12.5 OPEN TEXT CORPORATION 121
    • 12.5.1 COMPANY OVERVIEW 121
    • 12.5.2 FINANCIAL OVERVIEW 122
    • 12.5.3 PRODUCTS/SERVICES OFFERED 123
    • 12.5.4 KEY DEVELOPMENTS 123
    • 12.5.5 SWOT ANALYSIS 124
    • 12.5.6 KEY STRATEGIES 124
  • 12.6 LUMEDX 125
    • 12.6.1 COMPANY OVERVIEW 125
    • 12.6.2 FINANCIAL OVERVIEW 125
    • 12.6.3 PRODUCTS/SERVICES OFFERED 126
    • 12.6.4 KEY DEVELOPMENTS 126
    • 12.6.5 SWOT ANALYSIS 126
    • 12.6.6 KEY STRATEGIES 127
  • 12.7 MCKESSON CORPORATION 128
    • 12.7.1 COMPANY OVERVIEW 128
    • 12.7.2 FINANCIAL OVERVIEW 129
    • 12.7.3 PRODUCTS/SERVICES OFFERED 129
    • 12.7.4 KEY DEVELOPMENTS 129
    • 12.7.5 SWOT ANALYSIS 130
    • 12.7.6 KEY STRATEGIES 130
  • 12.8 OPTUM, INC. 131
    • 12.8.1 COMPANY OVERVIEW 131
    • 12.8.2 FINANCIAL OVERVIEW 131
    • 12.8.3 PRODUCTS/SERVICES OFFERED 132
    • 12.8.4 KEY DEVELOPMENTS 132
    • 12.8.5 SWOT ANALYSIS 133
    • 12.8.6 KEY STRATEGIES 133
  • 12.9 PHAMAX AG 134
    • 12.9.1 COMPANY OVERVIEW 134
    • 12.9.2 FINANCIAL OVERVIEW 134
    • 12.9.3 PRODUCTS/SERVICES OFFERED 134
    • 12.9.4 KEY DEVELOPMENTS 134
    • 12.9.5 SWOT ANALYSIS 135
    • 12.9.6 KEY STRATEGIES 135
  • 12.10 IBM 136
    • 12.10.1 COMPANY OVERVIEW 136
    • 12.10.2 FINANCIAL OVERVIEW 136
    • 12.10.3 PRODUCTS/SERVICES OFFERED 137
    • 12.10.4 KEY DEVELOPMENTS 137
    • 12.10.5 SWOT ANALYSIS 138
    • 12.10.6 KEY STRATEGIES 138
  • 12.11 IQVIA 139
    • 12.11.1 COMPANY OVERVIEW 139
    • 12.11.2 FINANCIAL OVERVIEW 140
    • 12.11.3 PRODUCTS/SERVICES OFFERED 140
    • 12.11.4 KEY DEVELOPMENTS 141
    • 12.11.5 SWOT ANALYSIS 141
    • 12.11.6 KEY STRATEGIES 142

13 APPENDIX 143

  • 13.1 REFERENCES 143
  • 13.2 RELATED REPORTS 143

Report You Might be Interested